RxDoctor Payments Data

Nicole Bielecki, PA

Physician Assistant · Greeley, CONPI 1619506060

Payments from drug & device makers

$5,446in general payments, 2019–2025

Across 248 payments — averaging $21.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$637
  • AbbVie$634
  • Sun Pharmaceutical Industries Inc.$614
  • Regeneron Healthcare Solutions, Inc.$547
  • Novartis$387
  • Johnson & Johnson$365
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$4,68686%
  • Education$76014%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,446 in reported general payments places this provider in the 95th percentile of 2,849 physician assistant providers in Colorado.

See all physician assistant providers in Colorado

Medicare billing

Part B allowed, 2024
$182,318
Medicare patients
348
Services billed
4,283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab55$215,042
Humira(Cf) PenAdalimumab13$180,440
Cosentyx Unoready PenSecukinumab12$130,694
Taltz AutoinjectorIxekizumab15$101,105
Dupixent SyringeDupilumab14$54,463
AdbryTralokinumab-Ldrm11$40,950
Clobetasol Propionate102$3,844
Tacrolimus23$3,615
Fluorouracil44$2,756
Ketoconazole134$1,871
Clindamycin Phosphate25$786
Triamcinolone Acetonide77$775
Doxycycline Monohydrate13$595
Minocycline Hcl15$431
Metronidazole13$397

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
LEO Pharma Inc.Adbry$235$40,95011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,849 physician assistant providers in Colorado.

Other physician assistant in Greeley

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →